NRG-BR003 - A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

https://clinicaltrials.gov/ct2/show/NCT02488967?term=NRG+BR003&rank=1

NRG-BR003
Cancer
Peter Bushunow, MD
Enrolling
Rachel O’Loughlin, RN BSN
(585) 747-4555